Novel chemotherapies in development for management of castration-resistant prostate cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference48 articles.
1. Cancer statistics, 2012.;Siegel;CA Cancer J Clin,2012
2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.;Petrylak;N Engl J Med,2004
3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.;Tannock;N Engl J Med,2004
4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.;Berthold;J Clin Oncol,2008
5. Microtubules and resistance to tubulin-binding agents.;Kavallaris;Nat Rev Cancer,2010
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Co‐delivery of docetaxel and retinoic acid by poly (ethylene glycol)‐retinoic acid conjugates based micelles for synergistic prostate cancer therapy;Micro & Nano Letters;2021-04-20
2. Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy;Journal of Materials Science;2020-02-28
3. Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs;Molecular Cancer Therapeutics;2019-11-11
4. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression;Cancer Letters;2019-03
5. Prostate changes related to therapy: with special reference to hormone therapy;Future Oncology;2014-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3